EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum and Nasal Lavage Fluid Eosinophil‐Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes

Saliha Selin Özuygur Ermis iD, Carina Malmhäll iD, Magnus P Borres iD, Robert Movérare iD, Daniil Lisik iD, Reshed Abohalaka iD, Selin Ercan iD, Susanne Schmeisser, Rani Basna iD, Roxana Mincheva iD, Göran Wennergren iD, Jan Lötvall iD und 4 weitere

Clinical and Translational Allergy · 2026-06 · 16 (6)

DOI: 10.1002/clt2.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 23.06.2026. Verfasst von Saliha Selin Özuygur Ermis und 15 weiteren Autor:innen. Beteiligte Einrichtung: Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VBG Group Herman Krefting Foundation for Asthma and Allergy Research, Sweden, Swedish Heart-Lung Foundation, Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As a surrogate for eosinophilic activation, eosinophil‐derived neurotoxin (EDN) is a potential clinical biomarker. However, EDN levels and discriminatory ability in different asthma phenotypes are unknown. We quantified serum and nasal lavage fluid (NLF) EDN levels and assessed the potential to differentiate clinically defined asthma phenotypes in an adult‐representative sample.

Methods

A total of 1499 serum and 386 NLF samples from individuals with current asthma obtained from the West Sweden Asthma Study were analyzed for EDN. Eosinophilic asthma was defined as blood eosinophil count of ≥ 300 cells/mm 3 , T2‐high asthma was defined as blood eosinophil count of ≥ 300 cells/mm 3 or fractional exhaled nitric oxide (FeNO) levels of ≥ 25 ppb. Other asthma phenotypes were defined based on presence of atopy, chronic rhinosinusitis (CRS), nasal polyposis, and obesity.

Results

Subjects with eosinophilic asthma had higher serum and NLF EDN levels than those with non‐eosinophilic asthma. In ROC analyses, serum EDN provided excellent discrimination between eosinophilic and non‐eosinophilic asthma (area under curve [AUC] = 0.84, 95% CI = 0.82–0.86); the corresponding AUC for NLF EDN was 0.67 (95% CI = 0.62–0.73). Serum and NLF EDN were higher in atopic asthma, T2‐high asthma, and asthma with nasal polyposis compared to their counterparts, but not in asthma with CRS. The highest absolute values of serum and NLF EDN were observed in the high eosinophil + FeNO group, followed by the high‐eosinophil‐only and high‐FeNO‐only groups.

Conclusion

Both serum and NLF EDN were higher in those with eosinophilic compared to non‐eosinophilic asthma. However, only serum EDN appears to distinguish eosinophilic asthma in ROC analyses.

Schlagwörter

Stichwörter der Autor:innen

adultasthmabiomarkereosinophileosinophil‐derived neurotoxin

Autor:innen und Institutionen

  • Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Thermo Fisher Scientific, Uppsala, Sweden.
  • Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
  • Department of Public Health and Clinical Medicine, Section of Sustainable Health, The OLIN Unit, Umeå University, Umeå, Sweden.
  • Department of Clinical Immunology, Sahlgrenska University Hospital, Gothenburg, Sweden.

ORCID-Profile: Saliha Selin Özuygur Ermis, Carina Malmhäll, Magnus P Borres, Robert Movérare, Daniil Lisik, Reshed Abohalaka, Selin Ercan, Rani Basna, Roxana Mincheva, Göran Wennergren, Jan Lötvall, Linda Ekerljung, Madeleine Rådinger, Hannu Kankaanranta, Bright I Nwaru

Förderung

  • VBG Group Herman Krefting Foundation for Asthma and Allergy Research, Sweden
  • Swedish Heart-Lung Foundation
  • Vetenskapsrådet
  • Astma-och Allergiförbundet
  • ALF agreement
  • Astma- och Allergiförbundet

Zitieren

APA

Özuygur Ermis, S. S., Malmhäll, C., Borres, M. P., Movérare, R., Lisik, D., Abohalaka, R., Ercan, S., Schmeisser, S., Basna, R., Mincheva, R., Wennergren, G., Lötvall, J., Ekerljung, L., Rådinger, M., Kankaanranta, H., & Nwaru, B. I. (2026). Serum and Nasal Lavage Fluid Eosinophil‐Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes. Clinical and Translational Allergy, 16(6). https://doi.org/10.1002/clt2.70183

Vancouver

Özuygur Ermis SS, Malmhäll C, Borres MP, Movérare R, Lisik D, Abohalaka R, et al. Serum and Nasal Lavage Fluid Eosinophil‐Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes. Clinical and Translational Allergy. 2026;16(6). doi:10.1002/clt2.70183

BibTeX
@article{zuygurErmis2026,
  author = {Özuygur Ermis, Saliha Selin and Malmhäll, Carina and Borres, Magnus P and Movérare, Robert and Lisik, Daniil and Abohalaka, Reshed and Ercan, Selin and Schmeisser, Susanne and Basna, Rani and Mincheva, Roxana and Wennergren, Göran and Lötvall, Jan and Ekerljung, Linda and Rådinger, Madeleine and Kankaanranta, Hannu and Nwaru, Bright I},
  title = {Serum and Nasal Lavage Fluid Eosinophil‐Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes},
  journal = {Clinical and Translational Allergy},
  year = {2026},
  volume = {16},
  number = {6},
  doi = {10.1002/clt2.70183}
}
Kostenlos starten →